Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival

Abstract

Abstract Aim Indications of drug therapies to elderly patients with hepatocellular carcinoma (HCC) should be carefully determined. The current study assessed the safety and efficacy of molecular targeted agents (MTAs) in the elderly patients with HCC, and identified factors associated with prognosis in a real‐world clinical setting. Methods In a retrospective observational study, clinical data of patients with unresectable HCC treated with sorafenib or lenvatinib as first‐line treatment at our hospital between 2011 and 2022, were investigated. Clinical parameters, therapeutic effects, adverse events (AEs), and prognosis were evaluated separately for the non‐elderly (<75 years old) and elderly patients (≥75 years old). Results Overall, 111 patients were enrolled, including 59 non‐elderly and 52 elderly patients. Compared to the non‐elderly patients, the elderly patients had significantly lower skeletal muscle mass and a significantly lower percentage of patients in poor general condition with performance status 2 or higher, but there were no differences in parameters related to liver function or nutritional status. There were no significant differences in the incidence of severe AEs and therapeutic effects between the groups. No significant difference in progression‐free survival was observed in the elderly and non‐elderly patients; however, overall survival (OS) for sorafenib treatment was shorter in the elderly patients than in the non‐elderly patients. Elderly patients consumed lower doses of both the drugs, and relative dose intensity (RDI) 4 weeks after treatment (4W‐RDI) was associated with OS. Further, OS in the elderly patients was significantly longer in the subgroup with high 4W‐RDI as compared to that in the subgroup with low 4W‐RDI. Conclusions MTAs can be safely administered to elderly patients with HCC. Furthermore, 4W‐RDI is associated with longer OS. Maintaining RDI in the early phase is crucial in predicting the success of treatment with MTAs, especially in the elderly patients.

Keywords

• hepatocellular carcinoma
• lenvatinib
• molecular targeted agent
• sorafenib
• tyrosine kinase inhibitor